Home

Overview

Strategy

Intelligence

Publications

Training

Meetings

Slide Presentations

Contact Us

Cardiovascular Biomarkers and Surrogate Endpoints Symposium
Bethesda, Maryland
September 18-20, 2006

As a service to our meeting attendees, the following presentation materials are available for viewing. Please note that material availability is at the discretion of our participating faculty.

If you've installed Windows SP 2, please allow your browser to show active content to view these files.

Login Required

1. The Role of Imaging in Disease Detection and Treatment - Dr. Jean-Claude Tardif
2. New Insights Based on Technological Advances and Landmark Trials - Dr. Robert Harrington
3. The FDA Critical Path Initiative - Opportunities and Challenges - Dr. Doublas Throckmorton
4. The Use of Biomarkers for FDA Regulatory Decision Making - Metabolism and Endocrine - Dr. Mary Parks
5. The Use of Biomarkers for FDA Regulatory Decision Making - Cardio-Renal - Dr. Norman Stockbridge
6. European Reg. View on CV Biomarkers and Surrogate Enpoints in Clinical Trials - Dr. Clemens Mittmann
7. The Use of Biomarkers for FDA Regulatory Decision Making - Health Claims - Dr. Paula Trumbo
8. Integrating Biomarkers into Practice: The Need for Data on Clinical Outcomes - Dr. Gurvaneet Randhawa
9. NIH Cardiovascular Biomarkers Initiatives - Dr. Christopher O'Donnell
10. Biomarkers in Heart Failure - Dr. James De Lemos
11. Targeted Molecular and Cellular Imaging - Dr. Jonathan Lindner
12. The Need for Biomarkers in Drug Development - Dr. David G. Orloff
13. Current Status of Disease Assessment with Carotid Ultrasound - Dr. Allen Taylor
14. Biomarkers in Acute Coronary Syndrome - Dr. David Morrow